A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404 · see citing works

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works

Alzheimer’s disease

Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works

Alzheimer’s Disease

Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works

Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease

Wang, X., Wang, W., Li, L., Perry, G., Lee, H.-G., & Zhu, X. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.10.015 · Cited by 1,357 · see citing works

Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics

Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., & Coon, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.020131 · Cited by 1,288 · see citing works

APP processing in Alzheimer’s disease.

Zhang, Y.-W., Thompson, R., Zhang, H., & Xu, H. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-3 · Cited by 983 · see citing works

Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature

Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · see citing works

Neurexin mediates the assembly of presynaptic terminals

Dean, C., Scholl, F. G., Choih, J., DeMaria, S., Berger, J., Isacoff, E., & Scheiffele, P. (2003) · Nature Neuroscience · doi:10.1038/nn1074 · Cited by 617 · see citing works

Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer

Gallien, S., Duriez, E., Crone, C., Kellmann, M., Moehring, T., & Domon, B. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.019802 · Cited by 510 · see citing works

The Chondroitin Sulfate Proteoglycans Neurocan and Phosphacan Are Expressed by Reactive Astrocytes in the Chronic CNS Glial Scar

McKeon, R. J., Jurynec, M. J., & Buck, C. R. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-24-10778.1999 · Cited by 480 · see citing works

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders

Abdi, F. A., Quinn, J. F., Jankovic, J. J., McIntosh, M. W., Leverenz, J. B., Peskind, E. R., Nixon, R., Nutt, J. G., Chung, K., Zabetian, C. P., et al. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9309 · Cited by 385 · see citing works

A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease

Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G. L., Burkhard, P. R., Hochstrasser, D. F., & Sanchez, J. (2003) · PROTEOMICS · doi:10.1002/pmic.200300470 · Cited by 375 · see citing works

The Extended Granin Family: Structure, Function, and Biomedical Implications

Bartolomucci, A., Possenti, R., Mahata, S. K., Fischer‐Colbrie, R., Loh, Y. P., & Salton, S. R. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0027 · Cited by 343 · see citing works

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 339 · see citing works

Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C).

Ghiso, J. A., Jensson, O., & Frangione, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.9.2974 · Cited by 332 · see citing works

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293 · see citing works

Narp and NP1 Form Heterocomplexes that Function in Developmental and Activity-Dependent Synaptic Plasticity

Xu, D., Hopf, C., Reddy, R., Cho, R. W., Guo, L., Lanahan, A., Petralia, R. S., Wenthold, R. J., O'Brien, R. J., & Worley, P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00463-x · Cited by 265 · see citing works

Cystatin C-Cathepsin B Axis Regulates Amyloid Beta Levels and Associated Neuronal Deficits in an Animal Model of Alzheimer's Disease

Sun, B., Zhou, Y., Halabisky, B., Lo, I., Cho, S.-H., Mueller-Steiner, S., Devidze, N., Wang, X., Grubb, A., & Gan, L. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.001 · Cited by 231 · see citing works

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1102 · Cited by 224 · see citing works

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients.

Nostrand, W. E. V., Wagner, S. L., Shankle, W. R., Farrow, J. S., Dick, M. B., Rozemüller, A. J. M., Kuiper, M. A., Wolters, E. C., Zimmerman, J. B., & Cotman, C. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2551 · Cited by 205 · see citing works

Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients

Davidsson, P., Brinkmalm, A., Nilsson, C. L., Lindbjer, M., Paulson, L., Andreasen, N., Gren, M., & Blennow, K. (2002) · Neuroreport · doi:10.1097/00001756-200204160-00015 · Cited by 200 · see citing works

Technical considerations for large-scale parallel reaction monitoring analysis

Gallien, S., Bourmaud, A., Kim, S.-Y., & Domon, B. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.10.029 · Cited by 198 · see citing works

Levels of α- and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients

Sennvik, K., Fastbom, J., Blomberg, M. E., Wahlund, L., Winblad, B., & Benedikz, E. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00929-5 · Cited by 193 · see citing works

Cystatin C inhibits amyloid-β deposition in Alzheimer's disease mouse models

Mi, W., Pawlik, M., Sastre, M., Jung, S. S., Radvinsky, D. S., Klein, A. M., Sommer, J., Schmidt, S. D., Nixon, R. A., Mathews, P. M., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.29 · Cited by 189 · see citing works

Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

Perrin, R. J., Craig‐Schapiro, R., Malone, J. P., Shah, A. R., Erdmann-Gilmore, P., Davis, A., Roe, C. M., Peskind, E. R., Li, G., Galasko, D. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016032 · Cited by 172 · see citing works

Codeposition of Cystatin C with Amyloid-β Protein in the Brain of Alzheimer Disease Patients

Levy, E., Sastre, M., Kumar, A. R., Gallo, G., Piccardo, P., Ghetti, B. F., & Tagliavini, F. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.1.94 · Cited by 172 · see citing works

A Critical Role for Neurofascin in Regulating Action Potential Initiation through Maintenance of the Axon Initial Segment

Zonta, B., Desmazières, A., Rinaldi, A., Tait, S., Sherman, D. L., Nolan, M. F., & Brophy, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.021 · Cited by 158 · see citing works

Apoptotic Pathways Mobilized in Microglia and Neurones as a Consequence of Chromogranin A‐Induced Microglial Activation

Kingham, P. J., Cuzner, M. L., & Pocock, J. M. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730538.x · Cited by 141 · see citing works

Cystatin C in aging and in Alzheimer’s disease

Mathews, P. M., & Levy, E. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.06.003 · Cited by 133 · see citing works

Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients

Olsson, A., Höglund, K., Sjögren, M. J. C., Andreasen, N., Minthon, L., Lannfelt, L., Büerger, K., Möller, H., Hampel, H. J., Davidsson, P., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00027-x · Cited by 132 · see citing works

Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity

Barthélemy, N. R., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Gabelle, A., Junot, C., Lehmann, S., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01001 · Cited by 123 · see citing works

Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers

Jahn, H., Wittke, S., Zürbig, P., Raedler, T. J., Arlt, S., Kellmann, M., Mullen, W., Eichenlaub, M., Mischak, H., & Wiedemann, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026540 · Cited by 116 · see citing works

Cystatin C Protects Neuronal Cells from Amyloid-β-induced Toxicity

Tizón, B., Ribé, E. M., Mi, W., Troy, C. M., & Levy, E. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1291 · Cited by 114 · see citing works

Clinical proteomics in neurodegenerative disorders

Zetterberg, H., Rüetschi, U., Portelius, E., Brinkmalm, G., Andréasson, U., Blennow, K., & Brinkmalm, A. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00985.x · Cited by 112 · see citing works

Reduced Levels of Amyloid-β-Binding Proteins in Cerebrospinal Fluid from Alzheimer's Disease Patients

Hansson, S., Andréasson, U., Wall, M., Skoog, I. G., Andreasen, N., Wallin, A., Zetterberg, H., & Blennow, K. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0966 · Cited by 112 · see citing works

Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.

Simonsen, A., Mcguire, J., Podust, V., Davies, H., Minthon, L., Skoog, I., Andreasen, N., Wallin, A., Waldemar, G., & Blennow, K. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.01.011 · Cited by 108 · see citing works

Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid

Palmert, M. R., Usiak, M., Mayeux, R. P., Raskind, M. A., Tourtellotte, W. W., & Younkin, S. G. (1990) · Neurology · doi:10.1212/wnl.40.7.1028 · Cited by 106 · see citing works

Serum cystatin C and the risk of Alzheimer disease in elderly men

Sundelöf, J. E., Ärnlöv, J., Ingelsson, E., Sundström, J., Basu, S., Zethelius, B., Larsson, A. O., Irizarry, M. C., Giedraitis, V., Rönnemaa, E., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326894.40353.93 · Cited by 106 · see citing works

A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ ₃₈ , Aβ ₄₀ , and Aβ ₄₂ in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls

Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., Höjrup, P., Minthon, L., Hansson, O., Zetterberg, H., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121471 · Cited by 105 · see citing works

Relative Increase in Alzheimer's Disease of Soluble Forms of Cerebral Aβ Amyloid Protein Precursor Containing the Kunitz Protease Inhibitory Domain

Moir, R. D., Lynch, T., Bush, A. I., Whyte, S., Henry, A., Portbury, S. D., Multhaup, G., Small, D. H., Tanzi, R. E., Beyreuther, K. T., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5013 · Cited by 103 · see citing works

Neuronal Pentraxin 1 Contributes to the Neuronal Damage Evoked by Amyloid-β and Is Overexpressed in Dystrophic Neurites in Alzheimer's Brain

Abad, M. A., Enguita, M., DeGregorio-Rocasolano, N., Ferrer, I., & Trullas, R. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-06.2006 · Cited by 102 · see citing works

Biochemical Evidence for the Long-Tail Form (Aβ1-42/43) of Amyloid β Protein as a Seed Molecule in Cerebral Deposits of Alzheimer′s Disease

Tamaoka, A., Kondo, T., Odaka, A., Sahara, N., Sawamura, N., Ozawa, K., Suzuki, N., Shoji, S., & Mori, H. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2740 · Cited by 101 · see citing works

An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics—Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Hölttä, M., Minthon, L., Hansson, O., Holmén-Larsson, J., Pike, I., Ward, M., Kuhn, K., Rüetschi, U., Zetterberg, H., Blennow, K., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr501076j · Cited by 100 · see citing works

CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease

Perneczky, R., Tsolakidou, A. F., Arnold, A., Diehl‐Schmid, J., Grimmer, T., Förstl, H., Kurz, A., & Alexopoulos, P. (2011) · Neurology · doi:10.1212/wnl.0b013e318221ad47 · Cited by 94 · see citing works

Neurofascin: A switch between neuronal plasticity and stability

Kriebel, M., Wuchter, J., Trinks, S., & Volkmer, H. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.01.012 · Cited by 86 · see citing works

A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer’s Disease versus Normal Aging and Frontotemporal Dementia

Simonsen, A. H., McGuire, J., Podust, V. N., Hagnelius, N.-O., Nilsson, T. K., Kapaki, E., Vassilopoulos, D., & Waldemar, G. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000110576 · Cited by 83 · see citing works

Processing of the Synaptic Cell Adhesion Molecule Neurexin-3β by Alzheimer Disease α- and γ-Secretases

Bot, N., Schweizer, C., Ben Halima, S., & Fraering, P. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.142521 · Cited by 81 · see citing works

Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β-Peptide in Alzheimer’s Disease and Major Depression – Inverse Correlation with Dementia Severity

Höck, C., Golombowski, S., Müller-Spahn, F., Naser, W. L., Beyreuther, K. T., Mönning, U., Schenk, D., Vigo‐Pelfrey, C., Bush, A. M., Moir, R. D., et al. (1998) · European Neurology · doi:10.1159/000007917 · Cited by 80 · see citing works

The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease

Pannee, J., Törnqvist, U., Westerlund, A., Ingelsson, M., Lannfelt, L., Brinkmalm, G., Persson, R., Gobom, J., Svensson, J., Johansson, P., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.04.041 · Cited by 74 · see citing works

Cystatin C reduces thein vitroformation of soluble Aβ1‐42 oligomers and protofibrils

Selenica, M. B., Wang, X., Ostergaard‐Pedersen, L., Westlind‐Danielsson, A., & GRUBB, A. O. (2006) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601009738 · Cited by 71 · see citing works

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid

Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 68 · see citing works

A role for the neurexin–neuroligin complex in Alzheimer's disease

Sindi, I. A., Tannenberg, R. K., & Dodd, P. R. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.032 · Cited by 64 · see citing works

Quantitative changes in the amyloid βA4 precursor protein in Alzheimer cerebrospinal fluid

Prior, R., Mönning, U., Schreiter-Gasser, U., Weidemann, A., Blennow, K., Gottfries, C. G., Masters, C. L., & Beyreuther, K. T. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90824-d · Cited by 63 · see citing works

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders

Mattsson, N., Insel, P. S., Nosheny, R. L., Zetterberg, H., Trojanowski, J. Q., Shaw, L. M. J., Tosun, D., Weiner, M. W., & Initiative, A. D. N. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.69 · Cited by 62 · see citing works

Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease

Helmfors, L., Boman, A., Civitelli, L., Nath, S., Sandin, L., Janefjord, C., McCann, H., Zetterberg, H., Blennow, K., Halliday, G. M., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.024 · Cited by 61 · see citing works

APP Processing and the APP-KPI Domain Involvement in the Amyloid Cascade

Menéndez‐González, M., Pérez‐Piñera, P., Martínez-Rivera, M., Calatayud, M. T. R., & Menes, B. B. (2005) · Neurodegenerative Diseases · doi:10.1159/000092315 · Cited by 58 · see citing works

Quantitative isoform-profiling of highly diversified recognition molecules

Schreiner, D., Simicevic, J., Ahrné, E., Schmidt, A., & Scheiffele, P. (2015) · eLife · doi:10.7554/elife.07794 · Cited by 56 · see citing works

Synaptic Proteins in Alzheimer's Disease

Marksteiner, J., Kaufman, W. A., Gurka, P., & Humpel, C. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:53 · Cited by 54 · see citing works

Neuronal Pentraxin 1 Negatively Regulates Excitatory Synapse Density and Synaptic Plasticity

Figueiro-Silva, J., Gruart, A., Clayton, K. B., Podlesniy, P., Abad, M. A., Gasull, X., Delgado-García, J. M., & Trullas, R. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2548-14.2015 · Cited by 53 · see citing works

The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure

Fargali, S., Garcia, A. L., Sadahiro, M., Jiang, C. S., Janssen, W. G. M., Lin, W., Cogliani, V., Elste, A. M., Mortillo, S., Cero, C., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-239509 · Cited by 52 · see citing works

Beta2-Microglobulin as a Diagnostic Marker in Cerebrospinal Fluid: A Follow-Up Study

Svatoňová, J., Bořecká, K., Adam, P., & Lánská, V. (2014) · Disease Markers · doi:10.1155/2014/495402 · Cited by 48 · see citing works

Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease

Brinkmalm, G., Brinkmalm, A., Bourgeois, P., Persson, R., Hansson, O., Portelius, E., Mercken, M. H., Andréasson, U., Parent, S., Lipari, F., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.03.019 · Cited by 47 · see citing works

Chromogranin A in Cerebrospinal Fluid: A Biochemical Marker for Synaptic Degeneration in Alzheimer’s Disease?

Blennow, K., Davidsson, P., Wallin, A., & Ekman, R. (1995) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106963 · Cited by 47 · see citing works

Explorative and targeted neuroproteomics in Alzheimer's disease

Brinkmalm, A., Portelius, E., Öhrfelt, A., Brinkmalm, G., Andréasson, U., Gobom, J., Blennow, K., & Zetterberg, H. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.01.009 · Cited by 45 · see citing works

Genetic Study of Neurexin and Neuroligin Genes in Alzheimer's Disease

Martinez-Mir, A., Initiative, A. D. N., González-Pérez, A., Gayán, J., Antúnez, C., Marín, J., Boada, M., Lopez-Arrieta, J. M., Fernández, E., Ramírez-Lorca, R., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122257 · Cited by 45 · see citing works

Redox State of Pentraxin 3 as a Novel Biomarker for Resolution of Inflammation and Survival in Sepsis

Cuello, F., Shankar‐Hari, M., Mayr, U., Yin, X., Marshall, M. J., Suna, G., Willeit, P., Langley, S. R., Jayawardhana, T., Zeller, T., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.039446 · Cited by 43 · see citing works

Amyloid‐β oligomers interact with neurexin and diminish neurexin‐mediated excitatory presynaptic organization

Naito, Y., Tanabe, Y., Lee, A. K., Hamel, E., & Takahashi, H. (2017) · Scientific Reports · doi:10.1038/srep42548 · Cited by 42 · see citing works

Chromogranin peptides in brain diseases

Willis, M., Leitner, I., Jellinger, K. A., & Marksteiner, J. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0648-z · Cited by 32 · see citing works

Expanding the cerebrospinal fluid endopeptidome

Hansson, K. T., Skillbäck, T. B., Pernevik, E., Kern, S., Portelius, E., Höglund, K., Brinkmalm, G., Holmén‐Larsson, J., Blennow, K., Zetterberg, H., et al. (2017) · PROTEOMICS · doi:10.1002/pmic.201600384 · Cited by 32 · see citing works

Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Moreno, J. A., Jakobsson, J., Mallucci, G. R., Zetterberg, H., Blennow, K., & Öhrfelt, A. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.040113 · Cited by 31 · see citing works

Pentraxins and Alzheimer's disease: At the interface between biomarkers and pharmacological targets

Osera, C., Pascale, A., Amadio, M., Venturini, L., Govoni, S. M., & Ricevuti, G. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.12.004 · Cited by 30 · see citing works

Cystatin C Shifts APP Processing from Amyloid-β Production towards Non-Amyloidgenic Pathway in Brain Endothelial Cells

Wang, X.-F., Liu, D.-X., Liang, Y., Xing, L.-L., Zhao, W.-H., Qin, X.-X., Shang, D.-S., Li, B., Fang, W.-G., Cao, L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161093 · Cited by 24 · see citing works

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry

Sjödin, S., Öhrfelt, A., Brinkmalm, G., Zetterberg, H., Blennow, K., & Brinkmalm, A. (2016) · Clinical Proteomics · doi:10.1186/s12014-016-9104-2 · Cited by 23 · see citing works

β-amyloid increases neurocan expression through regulating Sox9 in astrocytes: A potential relationship between Sox9 and chondroitin sulfate proteoglycans in Alzheimer's disease

Han, Y., Zhu, X., Xie, J., Zhao, Y., & Liu, X. (2016) · Brain Research · doi:10.1016/j.brainres.2016.06.010 · Cited by 23 · see citing works

Cerebrospinal fluid chromogranin A is unchanged in Alzheimer dementia

O’Connor, D. T., Kailasam, M. T., & Thal, L. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90011-y · Cited by 16 · see citing works

The value of the measurement of cerebrospinal fluid levels of lysozyme in the diagnosis of neurological disease.

Firth, G., Rees, J., & McKeran, R. O. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.7.709 · Cited by 13 · see citing works

Synaptic degeneration in Alzheimer disease

Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504 · see citing works

Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology

Rahman, M. M., & Lendel, C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00465-0 · Cited by 245 · see citing works

Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues

Muraoka, S., DeLeo, A. M., Sethi, M. K., Takamatsu-Yukawa, K., Yang, Z., Ko, J., Hogan, J., Ruan, Z., You, Y., Wang, Y., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12089 · Cited by 189 · see citing works

Fluid Biomarkers for Synaptic Dysfunction and Loss

Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

Duits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0335-x · Cited by 137 · see citing works

Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies

Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01276-6 · Cited by 132 · see citing works

Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer’s disease

Sathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Albert, M., Moghekar, A., & Pandey, A. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800105 · Cited by 126 · see citing works

Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration

Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112 · see citing works

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease

Kivisäkk, P., Carlyle, B. C., Sweeney, T., Quinn, J. P., Ramirez, C. E., Trombetta, B. A., Mendes, M., Brock, M., Rubel, C., Czerkowicz, J., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01002-x · Cited by 98 · see citing works

New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease

Park, S. A., Han, S. M., & Kim, C. E. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0418-9 · Cited by 93 · see citing works

VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice

El Gaamouch, F., Audrain, M., Lin, W.-J., Beckmann, N., Jiang, C., Hariharan, S., Heeger, P. S., Schadt, E. E., Gandy, S., Ehrlich, M. E., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0357-x · Cited by 92 · see citing works

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Sjödin, S., Brinkmalm, G., Öhrfelt, A., Parnetti, L., Paciotti, S., Hansson, O., Hardy, J., Blennow, K., Zetterberg, H., & Brinkmalm, A. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0533-9 · Cited by 91 · see citing works

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease

Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82 · see citing works

Amyloid precursor protein (APP) and amyloid β (Aβ) interact with cell adhesion molecules: Implications in Alzheimer’s disease and normal physiology

Pfundstein, G., Nikonenko, A. G., & Sytnyk, V. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.969547 · Cited by 83 · see citing works

Emerging evidence implicating a role for neurexins in neurodegenerative and neuropsychiatric disorders

Cuttler, K., Hassan, M., Carr, J. A., Cloete, R. E. A., & Bardien, S. (2021) · Open Biology · doi:10.1098/rsob.210091 · Cited by 71 · see citing works

Novel <scp>CSF</scp> biomarkers in genetic frontotemporal dementia identified by proteomics

van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez‐Valle, R., Graff, C., Öijerstedt, L., Grossman, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.745 · Cited by 65 · see citing works

A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease

Pedrero-Prieto, C. M., García‐Carpintero, S., Frontiñán-Rubio, J., Llanos-González, E., García, C. A., Alcain, F. J., Lindberg, I., Durán‐Prado, M., Peinado, J. R., & Rabanal‐Ruiz, Y. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09276-9 · Cited by 61 · see citing works

Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer’s disease

Hishimoto, A., Pletnikova, O., Lang, D. L., Troncoso, J. C., Egan, J. M., & Liu, Q.-R. (2019) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-019-0475-2 · Cited by 62 · see citing works

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia

Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E. (2023) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-023-01212-x · Cited by 50 · see citing works

Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias

Carlyle, B. C., Trombetta, B. A., & Arnold, S. E. (2018) · Proteomes · doi:10.3390/proteomes6030032 · Cited by 59 · see citing works

Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature review

Wesenhagen, K. E. J., Teunissen, C. E., Visser, P. J., & Tijms, B. M. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1670613 · Cited by 57 · see citing works

Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers

Remnestål, J., Öijerstedt, L., Ullgren, A., Olofsson, J., Bergström, S., Kultima, K., Ingelsson, M., Kilander, L., Uhlén, M., Månberg, A., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00198-y · Cited by 56 · see citing works

Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases

Minta, K., Brinkmalm, G., Janelidze, S., Sjödin, S., Portelius, E., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., & Andréasson, U. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00585-7 · Cited by 55 · see citing works

Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias

Teunissen, C. E., Kimble, L. E., Bayoumy, S., Bolsewig, K., Burtscher, F., Coppens, S., Das, S., Gogishvili, D., Gomes, B. F., José, N. G. D. S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100629 · Cited by 58 · see citing works

Improved Differential Diagnosis of Alzheimer’s Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers

Khoonsari, P. E., Shevchenko, G., Herman, S., Remnestål, J., Giedraitis, V., Brundin, R., Gunnarsson, M. D., Kilander, L., Zetterberg, H., Nilsson, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180855 · Cited by 51 · see citing works

Neuropeptides in Alzheimer’s Disease: An Update

Petrella, C., Certo, M. G. D., Barbato, C., Gabanella, F., Ralli, M., Greco, A., Possenti, R., & Severini, C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190503152555 · Cited by 53 · see citing works

Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer’s Disease

Bousiges, O., & Blanc, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126371 · Cited by 53 · see citing works

The Novel Omega-6 Fatty Acid Docosapentaenoic Acid Positively Modulates Brain Innate Immune Response for Resolving Neuroinflammation at Early and Late Stages of Humanized APOE-Based Alzheimer's Disease Models

Ma, Q., Zhu, C., Morselli, M., Su, T., Pelligrini, M., Lu, Z., Jones, M. R., Denver, P., Castro, D., Gu, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.558036 · Cited by 48 · see citing works

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

van Steenoven, I., Noli, B., Cocco, C., Ferri, G., Oeckl, P., Otto, M., Koel‐Simmelink, M. J. A., Bridel, C., van der Flier, W. M., Lemstra, A. W., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194674 · Cited by 42 · see citing works

Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia

Sogorb-Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., van Swieten, J. C., Seelaar, H., et al. (2022) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-022-01042-3 · Cited by 39 · see citing works

Structure, function, and pathology of Neurexin-3

Zhang, R., Jiang, H., Liu, Y., & He, G. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.04.008 · Cited by 37 · see citing works

A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study

Bergström, S., Öijerstedt, L., Remnestål, J., Olofsson, J., Ullgren, A., Seelaar, H., Swieten, J. C. V., Synofzik, M., Sánchez‐Valle, R., Moreno, F., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00499-4 · Cited by 36 · see citing works

VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD

Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease &amp; Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35 · see citing works

Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Dulewicz, M., Kulczyńska‐Przybik, A., & Mroczko, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218335 · Cited by 34 · see citing works

An increase in VGF expression through a rapid, transcription-independent, autofeedback mechanism improves cognitive function

Lin, W., Zhao, Y., Li, Z., Zheng, S., Zou, J., Warren, N. A., Bali, P., Wu, J., Xing, M., Jiang, C. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01489-2 · Cited by 33 · see citing works

Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease

Ma, Q., Teng, E., Zuo, X., Jones, M. R., Teter, B., Zhao, E. Y., Zhu, C., Bilousova, T. V., Gylys, K. H., Apostolova, L. G., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.014 · Cited by 32 · see citing works

VGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders

Wang, Y., Qin, X., Han, Y. J., & Li, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113099 · Cited by 33 · see citing works

Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer’s Disease

Minta, K., Brinkmalm, G., Portelius, E., Johansson, P., Svensson, J., Kettunen, P., Wallin, A., Zetterberg, H., Blennow, K., & Andréasson, U. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201039 · Cited by 31 · see citing works

Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond

Grasso, G. (2018) · Mass Spectrometry Reviews · doi:10.1002/mas.21566 · Cited by 30 · see citing works

Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer’s disease patients

Nilsson, J., Brinkmalm, G., Ramadan, S., Gilborne, L., Noborn, F., Blennow, K., Wallin, A., Svensson, J., Abo-Riya, M. A., Huang, X., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41897-5 · Cited by 29 · see citing works

Elevated urine histone 4 levels in women with ovarian endometriosis revealed by discovery and parallel reaction monitoring proteomics

Chen, X., Liu, H., Sun, W., Guo, Z., & Lang, J. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.103398 · Cited by 30 · see citing works

The emerging role of the chondroitin sulfate proteoglycan family in neurodegenerative diseases

Lin, J., Duan, M.-R., Lin, N., & Zhao, W. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0146 · Cited by 29 · see citing works

CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB

Lerche, S., Sjödin, S., Brinkmalm, A., Blennow, K., Wurster, I., Röeben, B., Zimmermann, M., Hauser, A., Liepelt‐Scarfone, I., Waniek, K., et al. (2021) · Movement Disorders · doi:10.1002/mds.28704 · Cited by 25 · see citing works

Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease

Gedam, M., & Zheng, H. (2024) · European Journal of Immunology · doi:10.1002/eji.202350815 · Cited by 23 · see citing works

Brevican and Neurocan Cleavage Products in the Cerebrospinal Fluid - Differential Occurrence in ALS, Epilepsy and Small Vessel Disease

Hußler, W., Höhn, L., Stolz, C., Vielhaber, S., Garz, C., Schmitt, F. C., Gundelfinger, E. D., Schreiber, S., & Seidenbecher, C. I. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.838432 · Cited by 23 · see citing works

Endosomal-Lysosomal and Autophagy Pathway in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Krance, S. H., Wu, C., Chan, A. C. Y., Kwong, S., Song, B. X., Xiong, L. Y., Ouk, M., Chen, M. H., Zhang, J., Yung, A., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220360 · Cited by 25 · see citing works

Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases

Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 21 · see citing works

Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor β-induced protein and improves survival in sepsis

Lee, W., Park, E. J., Kwon, O. K., Kim, H., Yoo, Y., Kim, S., Seo, Y., Kim, I.-S., Na, D. H., & Bae, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120000 · Cited by 21 · see citing works

Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer’s Disease

Enache, D., Pereira, J. B., Jelić, V., Winblad, B. G., Nilsson, P., Aarsland, D., & Bereczki, E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200498 · Cited by 21 · see citing works

Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus

Minta, K., Jeppsson, A., Brinkmalm, G., Portelius, E., Zetterberg, H., Blennow, K., Tullberg, M., & Andréasson, U. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00256-1 · Cited by 21 · see citing works

Protective exercise responses in the dentate gyrus of Alzheimer’s disease mouse model revealed with single-nucleus RNA-sequencing

da Rocha, J. F., Lance, M. L., Luo, R., Schlachter, P., Moreira, L., Iqbal, M. A., Kuhn, P., Gardner, R. S., Valaris, S., Islam, M. R., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01971-w · Cited by 19 · see citing works

TLQP-21 mediated activation of microglial BV2 cells promotes clearance of extracellular fibril amyloid-β

Cho, K., Jang, Y.-J., Lee, S.-J., Jeon, Y.-N., Shim, Y.-L., Lee, J., Lim, D.-S., Kim, D., & Yoon, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.111 · Cited by 19 · see citing works

Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ

Matafora, V., Gorb, A., Yang, F., Noble, W. J., Bachi, A., Perez‐Nievas, B. G., & Jiménez-Sánchez, M. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15875 · Cited by 18 · see citing works

Differential Proteome Analysis of Hybrid Bamboo (Bambusa pervariabilis × Dendrocalamopsis grandis) Under Fungal Stress (Arthrinium phaeospermum)

Li, S., Fang, X., Han, S., Zhu, T., & Zhu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-55229-0 · Cited by 17 · see citing works

Proteomics Landscape of Alzheimer’s Disease

Jain, A., & Sathe, G. J. (2021) · Proteomes · doi:10.3390/proteomes9010013 · Cited by 17 · see citing works

Extracellular Matrix Changes in Subcellular Brain Fractions and Cerebrospinal Fluid of Alzheimer’s Disease Patients

Höhn, L., Hußler, W., Richter, A., Smalla, K., Birkl-Toeglhofer, A. M., Birkl, C. R., Vielhaber, S., Leber, S. L., Gundelfinger, E. D., Haybaeck, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065532 · Cited by 17 · see citing works

CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review

Krause, K., Wulf, M., Sommer, P., Barkovits, K., Vorgerd, M., Marcus, K., & Eggers, B. (2021) · Diagnostics · doi:10.3390/diagnostics11091522 · Cited by 17 · see citing works

Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease

Barranco, N., Plá, V., Alcolea, D. A., Sánchez-Domínguez, I., Fischer‐Colbrie, R., Ferrer, I., Lleó, A., & Aguado, F. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00263-0 · Cited by 16 · see citing works

Isobaric Labeling Strategy Utilizing 4‑Plex N , N ‑Dimethyl Leucine (DiLeu) Tags Reveals Proteomic Changes Induced by Chemotherapy in Cerebrospinal Fluid of Children with B‑Cell Acute Lymphoblastic Leukemia

Yu, Q., Zhong, X., Chen, B., Yu, F., Ma, M., Diamond, C. A., Voeller, J., Kim, M. Y., DeSantes, K. B., Capitini, C. M., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00291 · Cited by 15 · see citing works

Exploring the Potential of Neuroproteomics in Alzheimer's Disease

Uddin, M. S., Kabir, M. T., Jakaria, M., Sobarzo‐Sánchez, E., Barreto, G. E., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200603112030 · Cited by 15 · see citing works

The Potential of ‘Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer’s Disease in African Americans

Stepler, K. E., & Robinson, R. A. S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-05542-4_1 · Cited by 15 · see citing works

Soluble Proteoglycans and Proteoglycan Fragments as Biomarkers of Pathological Extracellular Matrix Remodeling

Kemberi, M., Minns, A. F., & Santamaria, S. (2024) · Proteoglycan Research · doi:10.1002/pgr2.70011 · Cited by 16 · see citing works

Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid

Na, C. H., Sathe, G. J., Rosenthal, L. S., Moghekar, A., Dawson, V. L., Dawson, T. M., & Pandey, A. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09277-8 · Cited by 14 · see citing works

Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury

Minta, K., Brinkmalm, G., Thelin, E. P., Nimer, F. A., Piehl, F., Tullberg, M., Jeppsson, A., Portelius, E., Zetterberg, H., Blennow, K., et al. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.11.017 · Cited by 14 · see citing works

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry

Camporesi, E., Nilsson, J., Vrillon, A., Cognat, E., Hourrègue, C., Zetterberg, H., Blennow, K., Becker, B., Brinkmalm, A., Paquet, C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103793 · Cited by 13 · see citing works

Mass Spectrometry-Based Assay for Targeting Fifty-Two Proteins of Brain Origin in Cerebrospinal Fluid

Batruch, I., Lim, B., Soosaipillai, A. R., Brinc, D., Fiala, C., & Diamandis, E. P. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00087 · Cited by 11 · see citing works

Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis

Guldbrandsen, A., Lereim, R. R., Jacobsen, M., Garberg, H., Kroksveen, A. C., Barsnes, H., & Berven, F. S. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09296-5 · Cited by 11 · see citing works

Multiscale causal network models of Alzheimer’s disease identify VGF as a key regulator of diseasePreprint

Beckmann, N. D., Lin, W., Wang, M., Cohain, A. T., Wang, P., Ma, W., Wang, Y., Jiang, C. S., Audrain, M., Comella, P., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/458430 · Cited by 12 · see citing works

Biological Significance of the Protein Changes Occurring in the Cerebrospinal Fluid of Alzheimer’s Disease Patients: Getting Clues from Proteomic Studies

Pedrero-Prieto, C. M., Frontiñán-Rubio, J., Alcain, F. J., Durán‐Prado, M., Peinado, J. R., & Rabanal‐Ruiz, Y. (2021) · Diagnostics · doi:10.3390/diagnostics11091655 · Cited by 12 · see citing works

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease

Lowe, A. J., Sjödin, S., Rodrigues, F. B., Byrne, L. M., Blennow, K., Tortelli, R., Zetterberg, H., & Wild, E. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233820 · Cited by 10 · see citing works

Protofibrillar and Fibrillar Amyloid-β Binding Proteins in Cerebrospinal Fluid

Rahman, M. M., Westermark, G. T., Zetterberg, H., Härd, T., & Sandgren, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180596 · Cited by 9 · see citing works

Identification of tryptophan metabolism-related genes in immunity and immunotherapy in Alzheimer’s disease

Song, Z., Wu, Z., Luo, R., He, C., Li, Z., Yang, M., Yu, W., He, J., Deng, S., & Cheng, S. (2023) · Aging · doi:10.18632/aging.205220 · Cited by 10 · see citing works

Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer’s Disease

Shen, L., Xia, S., Zhang, H., Yao, F., Liu, X., Zhao, Y., Ying, M., Iqbal, J., & Liu, Q. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82035 · Cited by 10 · see citing works

Could VGF and/or its derived peptide act as biomarkers for the diagnosis of neurodegenerative diseases: A systematic review

Alqarni, S., & Alsebai, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032192 · Cited by 8 · see citing works

Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study

Johansson, K., Wasling, P., Novakova, L., Sjödin, S., Brinkmalm, A., Brinkmalm, G., Blennow, K., Zetterberg, H., & Axelsson, M. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103846 · Cited by 8 · see citing works

The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization

Osse, A. M. L., Kinney, J., & Cummings, J. L. (2025) · Alzheimer's & Dementia · doi:10.1002/trc2.70050 · Cited by 11 · see citing works

Proteomic and Biological Profiling of Extracellular Vesicles from Alzheimer’s Disease Human Brain TissuesPreprint

Muraoka, S., DeLeo, A. M., Sethi, M. K., Takamatsu-Yukawa, K., Yang, Z., Ko, J., Hogan, J., Ruan, Z., You, Y., Wang, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/733477 · Cited by 7 · see citing works

Increased levels of the synaptic proteins PSD-95, SNAP-25, and Neurogranin in the cerebrospinal fluid of patients with Alzheimer’s DiseasePreprint

Kivisäkk, P., Carlyle, B. C., Sweeney, T., Quinn, J. P., Ramirez, C. E., Trombetta, B. A., Mendes, M., Brock, M. J., Rubel, C. E., Czerkowicz, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1366881/v1 · Cited by 7 · see citing works

Diagnostic value of CSF chromogranin A to discriminate between Alzheimer's disease and dementia with Lewy bodies

Bousiges, O., Lavaux, T., Demuynck, C., Schaeffer‐Agalède, C., Philippi, N., Muller, C., Cretin, B., & Blanc, F. (2024) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12961 · Cited by 6 · see citing works

Differential patterns of lysosomal dysfunction are seen in the clinicopathological forms of primary progressive aphasia

Swift, I. J., Sjödin, S., Gobom, J., Brinkmalm, A., Blennow, K., Zetterberg, H., Rohrer, J. D., & Sogorb‐Esteve, A. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12063-9 · Cited by 6 · see citing works

Secretogranin III upregulation is involved in parkinsonian toxin-mediated astroglia activation

Zhan, X., Wen, G., Jiang, E., Li, F., Wu, X., & Pang, H. (2020) · The Journal of Toxicological Sciences · doi:10.2131/jts.45.271 · Cited by 6 · see citing works

Targeted co-expression networks for the study of traits

Gómez-Pascual, A., Rocamora-Perez, G., Ibanez, L., & Botía, J. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-67329-7 · Cited by 5 · see citing works

Differential Impairment of Cerebrospinal Fluid Synaptic Biomarkers in the Genetic Forms of Frontotemporal DementiaPreprint

Sogorb‐Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Russell, L. L., Peakman, G., Convery, R. S., Swieten, J. C. V., Seelaar, H., Borroni, B., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1188941/v1 · Cited by 5 · see citing works

Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways

Kirsebom, B., Nilsson, J., Vromen, E., Arnesen, P. M., Bjørnerud, A., Brinkmalm, A., Bråthen, G., Grøntvedt, G. R., Jarholm, J. A., Nordengen, K., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00899-w · Cited by 4 · see citing works

Endo‐lysosomal protein concentrations in CSF from patients with frontotemporal dementia caused by CHMP2B mutation

Toft, A. D., Sjödin, S., Simonsen, A. H., Ejlerskov, P., Roos, P., Musaeus, C. S., Henriksen, E. E., Nielsen, T. T., Brinkmalm, A., Blennow, K., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12402 · Cited by 3 · see citing works

An astrocyte-derived cytokine TIMP-1 restores synaptic plasticity in an Alzheimer’s disease modelPreprint

Sarkar, S., Gharami, K., Paidi, R. K., Srikumar, B. N., & Biswas, S. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.18.533245 · Cited by 4 · see citing works

Heterogeneity of cerebral atrophic rate in mild cognitive impairment and its interactive association with proteins related to microglia activity on longitudinal cognitive changes

Tang, J., Cao, Z., Lei, M., Yu, Q., Mai, Y., Xu, J., Liao, W., Ruan, Y., Shi, L., Yang, L., et al. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105582 · Cited by 2 · see citing works

Surrogate Cerebrospinal Fluid Biomarkers for Assessing the Efficacy of Gene Therapy in Hurler Syndrome

Haseloff, R. F., Trudel, S., Birke, R., Schümann, M., Krause, E., Gomila, C., Heard, J., Blasig, I. E., & Ausseil, J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.640547 · Cited by 2 · see citing works

Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric AßPreprint

Matafora, V., Gorb, A., Noble, W., Bachi, A., Perez-Nievas, B., & Jimenez-Sanchez, M. (2023) · bioRxiv · doi:10.1101/2023.01.18.523916

MU-BRAIN: MUltiethnic Brain Rna-seq for Alzheimer INitiativePreprint

Yang, Z., Cieza, B., Reyes‐Dumeyer, D., Lee, A., Ma, Y., Yılmaz, E., Lantigua, R., Miller, G. W., Brown, L. M., Honig, L. S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.20.581250 · Cited by 2 · see citing works

Basal Forebrain Deep Brain Stimulation Impacts the Regulation of Extracellular Vesicle Related Proteins in the Rat BrainPreprint

Li, W., Lozano‐Montes, L., Nair, J., Dimanico, M., Mazloum, R., Hu, Z., Scolari, B., Dengjel, J., Theilig, F., Harvey, M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/374256

Essential Features and Use Cases of the Cerebrospinal Fluid Proteome Resource (CSF-PR)

Guldbrandsen, A., Farag, Y. M., Lereim, R. R., Berven, F. S., & Barsnes, H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9706-0_25

Quantification of the Trans-Synaptic Partners Neuroligin-Neurexin in CSF of Neurodegenerative Diseases by Parallel Reaction Monitoring Mass SpectrometryPreprint

Camporesi, E., Nilsson, J., Vrillon, A., Cognat, E., Hourrègue, C., Zetterberg, H., Blennow, K., Becker, B., Brinkmalm, A., Paquet, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3915425

Differential Impairment Of Cerebrospinal Fluid Synaptic Biomarkers In The Genetic Forms Of Frontotemporal DementiaPreprint

Sogorb‐Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Russell, L. L., Peakman, G., Convery, R. S., Swieten, J. C. V., Seelaar, H., Borroni, B., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1188941/v2

Cell adhesion proteins in the cerebrospinal fluid of neonates prenatally exposed to Zika virus: A case–control study

Ramos, C. L., Nascimento‐Carvalho, E. C., Nascimento‐Carvalho, G. C., VanDuijn, M. M., Vilas‐Boas, A., Moreno-carvalho, O. A., Carvalho, L. P., Zeneyedpour, L., Ferwerda, G., de Groot, R., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15851

CEREBROSPINAL FLUID EVALUATION AS A DIAGNOSIS AND PROGNOSIS TOOL: A BIBLIOMETRIC ANALYSIS OF THE 100 MOST CITED ARTICLES

Filho, L. C. F., Aranha, M. F. D. A. C., Cabeça, R. A. S., Massoud, R. O., Cohen, S. B., Fernandes, L. M. P., de Oliveira, R. D. C. S., & Cohen, P. B. (2023) · Arquivos de Ciências da Saúde da UNIPAR · doi:10.25110/arqsaude.v27i10.2023-012

Additional file 1 of Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid

Na, C. H., Sathe, G. J., Rosenthal, L. S., Moghekar, A., Dawson, V. L., Dawson, T. M., & Pandey, A. (2020) · Figshare · doi:10.6084/m9.figshare.12246554

Additional file 4 of Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid

Na, C. H., Sathe, G. J., Rosenthal, L. S., Moghekar, A., Dawson, V. L., Dawson, T. M., & Pandey, A. (2020) · Figshare · doi:10.6084/m9.figshare.12246581

Additional file 3 of Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid

Na, C. H., Sathe, G. J., Rosenthal, L. S., Moghekar, A., Dawson, V. L., Dawson, T. M., & Pandey, A. (2020) · Figshare · doi:10.6084/m9.figshare.12246575

Additional file 1 of Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus

Minta, K., Jeppsson, A., Brinkmalm, G., Portelius, E., Zetterberg, H., Blennow, K., Tullberg, M., & Andréasson, U. (2021) · Figshare · doi:10.6084/m9.figshare.14594250

[P1–268]: ANALYSIS OF NEW POTENTIAL CSF BIOMARKERS FOR ALZHEIMER's DISEASE BY PARALLEL REACTION MONITORING MASS SPECTROMETRY

Brinkmalm, G., Simonsen, A. H., Sjödin, S., Hasselbalch, S. G., Zetterberg, H., Blennow, K., & Brinkmalm, A. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.284

Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease

Andersson, A. K., Remnestål, J., Nellgård, B., Vunk, H., Kotol, D., Edfors, F., Uhlén, M., Schwenk, J. M., Ilag, L. L., Zetterberg, H., et al. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.03.243 · Cited by 50 · see citing works

Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer’s disease

Sathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Albert, M., Moghekar, A., & Pandey, A. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800105 · Cited by 126 · see citing works

Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease

Zhou, M., Haque, R. U., Dammer, E. B., Duong, D. M., Ping, L., Johnson, E. C. B., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09285-8 · Cited by 92 · see citing works

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer’s Disease

Watson, C. M., Dammer, E. B., Ping, L., Duong, D. M., Modeste, E. S., Carter, E. K., Johnson, E. C. B., Levey, A. I., Lah, J. J., Roberts, B. R., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02158-3 · Cited by 61 · see citing works